The $110M upfront provides immediate cash runway and validates HUTCHMED's ATTC platform. Monitor the Phase I start in H2 2026 and any early clinical data readouts. The GSK partnership significantly de-risks development costs and adds a major pharma partner, which could drive re-rating. Watch for potential antitrust clearance as a near-term catalyst.
HCM drugs
HCM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 3 $14.11entry
- T+1 · 2mo ago −0.14%α +0.24% · $14.09
- T+5 · 2mo ago −9.14%α −7.99% · $12.82
- T+20 · 7w ago +0.64%α +1.83% · $14.20
- T+51 · todayOpen
- T+60 · in 13d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED announced an exclusive worldwide licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC) for colorectal, pancreatic, and lung cancers. The deal includes a $110 million upfront payment and up to $1.295 billion in total milestones plus tiered royalties, with HUTCHMED retaining rights in Greater China. This is a major non-dilutive validation of HUTCHMED's ATTC platform and provides significant near-term cash, though the asset is still pre-clinical with Phase I starting H2 2026.
Key Facts
- HUTCHMED licensed HMPL-A830 (KRAS-EGFR ATTC) to GSK for ex-China rights.
- Upfront payment of $110 million; total potential milestones up to $1.295 billion plus tiered royalties.
- HUTCHMED retains full rights in Mainland China, Hong Kong, Macau, and Taiwan.
- GSK gets right of first negotiation on one earlier-stage ATTC candidate.
- Phase I clinical trial expected to start H2 2026 (NCT07718581).
- BofA Securities acted as exclusive financial advisor to HUTCHMED.
Financial Impact
$110 million upfront + up to $1.185 billion in milestones + tiered royalties on net sales
Risk Factors
- Deal subject to customary closing conditions including antitrust regulatory reviews.
- HMPL-A830 is pre-clinical; Phase I has not yet started and clinical data may not replicate preclinical results.
- Milestone payments are contingent on development and regulatory success, which is uncertain.
- GSK has a right of first negotiation on one earlier-stage ATTC candidate, potentially limiting future partnering optionality.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000057 |
| Document: hcm-20260903x6k.htm | 0001648257-26-000057 |
| Document: 0001648257-26-000057-index-headers.html | 0001648257-26-000057 |
| Document: 0001648257-26-000057-index.html | 0001648257-26-000057 |
| Document: 0001648257-26-000057.txt | 0001648257-26-000057 |
Track record
33 reports on HCM
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers